Question special

Many articles have pointed out that extensions are no longer ways for pharmaceutical companies to be rewarded for real innovations. Rather, they are a mechanism used by these companies to essentially milk every last dollar they can from minor changes in the drug (isomerization, different coating, different route of administration among others) that has little to no clinical benefit. Do you think this is a harsh or accurate assessment, and if accurate, how do we pressure this to change?